Medexus Pharmaceuticals Q3 2024 Earnings Report

Medexus Pharmaceuticals EPS Results

• Actual EPS: -C$0.03
• Consensus EPS: C$0.10
• Beat/Miss: Missed by -C$0.13
• One Year Ago EPS: N/A

Medexus Pharmaceuticals Revenue Results

• Actual Revenue: $34.33 million
• Expected Revenue: $42.33 million
• Beat/Miss: Missed by -$8.00 million
• YoY Revenue Growth: N/A

Medexus Pharmaceuticals Announcement Details

• Quarter: Q3 2024
• Date: 2/7/2024
• Time: N/A

Medexus Pharmaceuticals (TSE:MDP) operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.